Global Extended-release Medication market size is predicted to grow from US$ 41340 million in 2025 to US$ 61470 million in 2031; it is expected to grow at a CAGR of 6.8% from 2025 to 2031.

Global Extended-release Medication Market Growth (Status and Outlook) 2025-2031

The global Extended-release Medication market size is predicted to grow from US$ 41340 million in 2025 to US$ 61470 million in 2031; it is expected to grow at a CAGR of 6.8% from 2025 to 2031. Extended-release Medication refers to pharmaceutical drugs designed to release their active ingredients gradually over an extended period within the body. This controlled-release mechanism allows for a more stable and prolonged therapeutic effect, reducing the need for frequent dosing and minimizing potential side effects. Extended-release medications are commonly used for treating chronic conditions like hypertension, diabetes, and pain management. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. LPI (LP Information) newest research report, the Extended-release Medication Industry Forecast looks at past sales and reviews total world Extended-release Medication sales in 2024, providing a comprehensive analysis by region and market sector of projected Extended-release Medication sales for 2025 through 2031. With Extended-release Medication sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Extended-release Medication industry. This Insight Report provides a comprehensive analysis of the global Extended-release Medication landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Extended-release Medication portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Extended-release Medication market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Extended-release Medication and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Extended-release Medication. This report presents a comprehensive overview, market shares, and growth opportunities of Extended-release Medication market by product type, application, key players and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Original Medication &nbsp;&nbsp;&nbsp; Generic Medication Segmentation by Application: &nbsp;&nbsp;&nbsp; Hospital &nbsp;&nbsp;&nbsp; Drugstore &nbsp;&nbsp;&nbsp; Other This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Sanofi &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Bayer &nbsp;&nbsp;&nbsp; Johnson & Johnson &nbsp;&nbsp;&nbsp; Takeda &nbsp;&nbsp;&nbsp; AstraZeneca &nbsp;&nbsp;&nbsp; AbbVie &nbsp;&nbsp;&nbsp; Pfizer &nbsp;&nbsp;&nbsp; Collegium Pharmaceutical, Inc &nbsp;&nbsp;&nbsp; Endo Pharmaceuticals &nbsp;&nbsp;&nbsp; Shanghai Shyndec Pharmaceutical &nbsp;&nbsp;&nbsp; Zhuhai Rundu Pharmaceutical &nbsp;&nbsp;&nbsp; China Res Double-Crane

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Extended-release Medication Market Size (2020-2031) &nbsp;2.1.2 Extended-release Medication Market Size CAGR by Region (2020 VS 2024 VS 2031) &nbsp;2.1.3 World Current & Future Analysis for Extended-release Medication by Country/Region (2020, 2024 & 2031) &nbsp;2.2 Extended-release Medication Segment by Type &nbsp;2.2.1 Original Medication &nbsp;2.2.2 Generic Medication &nbsp;2.3 Extended-release Medication Market Size by Type &nbsp;2.3.1 Extended-release Medication Market Size CAGR by Type (2020 VS 2024 VS 2031) &nbsp;2.3.2 Global Extended-release Medication Market Size Market Share by Type (2020-2025) &nbsp;2.4 Extended-release Medication Segment by Application &nbsp;2.4.1 Hospital &nbsp;2.4.2 Drugstore &nbsp;2.4.3 Other &nbsp;2.5 Extended-release Medication Market Size by Application &nbsp;2.5.1 Extended-release Medication Market Size CAGR by Application (2020 VS 2024 VS 2031) &nbsp;2.5.2 Global Extended-release Medication Market Size Market Share by Application (2020-2025) 3 Extended-release Medication Market Size by Player &nbsp;3.1 Extended-release Medication Market Size Market Share by Player &nbsp;3.1.1 Global Extended-release Medication Revenue by Player (2020-2025) &nbsp;3.1.2 Global Extended-release Medication Revenue Market Share by Player (2020-2025) &nbsp;3.2 Global Extended-release Medication Key Players Head office and Products Offered &nbsp;3.3 Market Concentration Rate Analysis &nbsp;3.3.1 Competition Landscape Analysis &nbsp;3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.4 New Products and Potential Entrants &nbsp;3.5 Mergers & Acquisitions, Expansion 4 Extended-release Medication by Region &nbsp;4.1 Extended-release Medication Market Size by Region (2020-2025) &nbsp;4.2 Global Extended-release Medication Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Extended-release Medication Market Size Growth (2020-2025) &nbsp;4.4 APAC Extended-release Medication Market Size Growth (2020-2025) &nbsp;4.5 Europe Extended-release Medication Market Size Growth (2020-2025) &nbsp;4.6 Middle East & Africa Extended-release Medication Market Size Growth (2020-2025) 5 Americas &nbsp;5.1 Americas Extended-release Medication Market Size by Country (2020-2025) &nbsp;5.2 Americas Extended-release Medication Market Size by Type (2020-2025) &nbsp;5.3 Americas Extended-release Medication Market Size by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Extended-release Medication Market Size by Region (2020-2025) &nbsp;6.2 APAC Extended-release Medication Market Size by Type (2020-2025) &nbsp;6.3 APAC Extended-release Medication Market Size by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia 7 Europe &nbsp;7.1 Europe Extended-release Medication Market Size by Country (2020-2025) &nbsp;7.2 Europe Extended-release Medication Market Size by Type (2020-2025) &nbsp;7.3 Europe Extended-release Medication Market Size by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Extended-release Medication by Region (2020-2025) &nbsp;8.2 Middle East & Africa Extended-release Medication Market Size by Type (2020-2025) &nbsp;8.3 Middle East & Africa Extended-release Medication Market Size by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Global Extended-release Medication Market Forecast &nbsp;10.1 Global Extended-release Medication Forecast by Region (2026-2031) &nbsp;10.1.1 Global Extended-release Medication Forecast by Region (2026-2031) &nbsp;10.1.2 Americas Extended-release Medication Forecast &nbsp;10.1.3 APAC Extended-release Medication Forecast &nbsp;10.1.4 Europe Extended-release Medication Forecast &nbsp;10.1.5 Middle East & Africa Extended-release Medication Forecast &nbsp;10.2 Americas Extended-release Medication Forecast by Country (2026-2031) &nbsp;10.2.1 United States Market Extended-release Medication Forecast &nbsp;10.2.2 Canada Market Extended-release Medication Forecast &nbsp;10.2.3 Mexico Market Extended-release Medication Forecast &nbsp;10.2.4 Brazil Market Extended-release Medication Forecast &nbsp;10.3 APAC Extended-release Medication Forecast by Region (2026-2031) &nbsp;10.3.1 China Extended-release Medication Market Forecast &nbsp;10.3.2 Japan Market Extended-release Medication Forecast &nbsp;10.3.3 Korea Market Extended-release Medication Forecast &nbsp;10.3.4 Southeast Asia Market Extended-release Medication Forecast &nbsp;10.3.5 India Market Extended-release Medication Forecast &nbsp;10.3.6 Australia Market Extended-release Medication Forecast &nbsp;10.4 Europe Extended-release Medication Forecast by Country (2026-2031) &nbsp;10.4.1 Germany Market Extended-release Medication Forecast &nbsp;10.4.2 France Market Extended-release Medication Forecast &nbsp;10.4.3 UK Market Extended-release Medication Forecast &nbsp;10.4.4 Italy Market Extended-release Medication Forecast &nbsp;10.4.5 Russia Market Extended-release Medication Forecast &nbsp;10.5 Middle East & Africa Extended-release Medication Forecast by Region (2026-2031) &nbsp;10.5.1 Egypt Market Extended-release Medication Forecast &nbsp;10.5.2 South Africa Market Extended-release Medication Forecast &nbsp;10.5.3 Israel Market Extended-release Medication Forecast &nbsp;10.5.4 Turkey Market Extended-release Medication Forecast &nbsp;10.6 Global Extended-release Medication Forecast by Type (2026-2031) &nbsp;10.7 Global Extended-release Medication Forecast by Application (2026-2031) &nbsp;10.7.1 GCC Countries Market Extended-release Medication Forecast 11 Key Players Analysis &nbsp;11.1 Sanofi &nbsp;11.1.1 Sanofi Company Information &nbsp;11.1.2 Sanofi Extended-release Medication Product Offered &nbsp;11.1.3 Sanofi Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.1.4 Sanofi Main Business Overview &nbsp;11.1.5 Sanofi Latest Developments &nbsp;11.2 Novartis &nbsp;11.2.1 Novartis Company Information &nbsp;11.2.2 Novartis Extended-release Medication Product Offered &nbsp;11.2.3 Novartis Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.2.4 Novartis Main Business Overview &nbsp;11.2.5 Novartis Latest Developments &nbsp;11.3 Bayer &nbsp;11.3.1 Bayer Company Information &nbsp;11.3.2 Bayer Extended-release Medication Product Offered &nbsp;11.3.3 Bayer Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.3.4 Bayer Main Business Overview &nbsp;11.3.5 Bayer Latest Developments &nbsp;11.4 Johnson & Johnson &nbsp;11.4.1 Johnson & Johnson Company Information &nbsp;11.4.2 Johnson & Johnson Extended-release Medication Product Offered &nbsp;11.4.3 Johnson & Johnson Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.4.4 Johnson & Johnson Main Business Overview &nbsp;11.4.5 Johnson & Johnson Latest Developments &nbsp;11.5 Takeda &nbsp;11.5.1 Takeda Company Information &nbsp;11.5.2 Takeda Extended-release Medication Product Offered &nbsp;11.5.3 Takeda Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.5.4 Takeda Main Business Overview &nbsp;11.5.5 Takeda Latest Developments &nbsp;11.6 AstraZeneca &nbsp;11.6.1 AstraZeneca Company Information &nbsp;11.6.2 AstraZeneca Extended-release Medication Product Offered &nbsp;11.6.3 AstraZeneca Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.6.4 AstraZeneca Main Business Overview &nbsp;11.6.5 AstraZeneca Latest Developments &nbsp;11.7 AbbVie &nbsp;11.7.1 AbbVie Company Information &nbsp;11.7.2 AbbVie Extended-release Medication Product Offered &nbsp;11.7.3 AbbVie Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.7.4 AbbVie Main Business Overview &nbsp;11.7.5 AbbVie Latest Developments &nbsp;11.8 Pfizer &nbsp;11.8.1 Pfizer Company Information &nbsp;11.8.2 Pfizer Extended-release Medication Product Offered &nbsp;11.8.3 Pfizer Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.8.4 Pfizer Main Business Overview &nbsp;11.8.5 Pfizer Latest Developments &nbsp;11.9 Collegium Pharmaceutical, Inc &nbsp;11.9.1 Collegium Pharmaceutical, Inc Company Information &nbsp;11.9.2 Collegium Pharmaceutical, Inc Extended-release Medication Product Offered &nbsp;11.9.3 Collegium Pharmaceutical, Inc Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.9.4 Collegium Pharmaceutical, Inc Main Business Overview &nbsp;11.9.5 Collegium Pharmaceutical, Inc Latest Developments &nbsp;11.10 Endo Pharmaceuticals &nbsp;11.10.1 Endo Pharmaceuticals Company Information &nbsp;11.10.2 Endo Pharmaceuticals Extended-release Medication Product Offered &nbsp;11.10.3 Endo Pharmaceuticals Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.10.4 Endo Pharmaceuticals Main Business Overview &nbsp;11.10.5 Endo Pharmaceuticals Latest Developments &nbsp;11.11 Shanghai Shyndec Pharmaceutical &nbsp;11.11.1 Shanghai Shyndec Pharmaceutical Company Information &nbsp;11.11.2 Shanghai Shyndec Pharmaceutical Extended-release Medication Product Offered &nbsp;11.11.3 Shanghai Shyndec Pharmaceutical Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.11.4 Shanghai Shyndec Pharmaceutical Main Business Overview &nbsp;11.11.5 Shanghai Shyndec Pharmaceutical Latest Developments &nbsp;11.12 Zhuhai Rundu Pharmaceutical &nbsp;11.12.1 Zhuhai Rundu Pharmaceutical Company Information &nbsp;11.12.2 Zhuhai Rundu Pharmaceutical Extended-release Medication Product Offered &nbsp;11.12.3 Zhuhai Rundu Pharmaceutical Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.12.4 Zhuhai Rundu Pharmaceutical Main Business Overview &nbsp;11.12.5 Zhuhai Rundu Pharmaceutical Latest Developments &nbsp;11.13 China Res Double-Crane &nbsp;11.13.1 China Res Double-Crane Company Information &nbsp;11.13.2 China Res Double-Crane Extended-release Medication Product Offered &nbsp;11.13.3 China Res Double-Crane Extended-release Medication Revenue, Gross Margin and Market Share (2020-2025) &nbsp;11.13.4 China Res Double-Crane Main Business Overview &nbsp;11.13.5 China Res Double-Crane Latest Developments 12 Research Findings and Conclusion

Buyer Information

Order Summary

Report	Global Extended-release Medication Market Growth (Status and Outlook) 2025-2031
Selected License	Multi ID: LPI38894